Defining phenotypes of long-term lithium and valproate response, including combination therapy: a modified application of the Alda scale in patients with bipolar disorders

International Journal of Bipolar Disorders
Jinyoung LeeKyung Sue Hong

Abstract

When evaluating the long-term treatment response to mood stabilizers using the Alda scale, mood stabilizer combination therapy is typically considered a confounding factor, and patients receiving combination therapy are excluded from the analysis. However, this may result in bias if those under combination therapy are worse treatment responders. This study aims to explore whether the Alda scale is applicable to patients taking lithium and valproate combination therapy. We compared long-term treatment response in patients receiving monotherapy and combination therapy of the two drugs, and investigated clinical correlates of the responses to each drug. The study subjects consisted of 102 patients with bipolar I (BD-I) or bipolar II (BD-II) disorder who had been undergoing maintenance treatment with lithium and/or valproate for more than 2 years at a single specialized bipolar disorder clinic. Long-term treatment response was measured using the Alda scale and compared among the lithium monotherapy group, the valproate monotherapy group, and the mood stabilizer combination group. Clinical correlates of long-term treatment response were evaluated in lithium users and valproate users separately. There were no significant differences ...Continue Reading

References

Nov 6, 2002·The Journal of Clinical Psychiatry·Paul GrofMartin Alda
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laszlo GyulaiPatricia J Wozniak
May 5, 2004·Comprehensive Psychiatry·Eun-Jeong JooYong Sik Kim
Jul 4, 2006·The British Journal of Psychiatry : the Journal of Mental Science·M W OttoUNKNOWN STEP-BD Investigators
Apr 20, 2007·Journal of Affective Disorders·Julie GarnhamMartin Alda
Apr 14, 2010·Molecular Psychiatry·M T M LeeA T A Cheng
Jan 10, 2013·Pharmacological Reviews·Chi-Tso ChiuDe-Maw Chuang
Mar 14, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
Oct 18, 2013·The Cochrane Database of Systematic Reviews·Andrea CiprianiJohn Geddes
Dec 30, 2014·Journal of Affective Disorders·M ShashidharaY C Janardhan Reddy
May 23, 2015·Neuropsychiatric Disease and Treatment·Allan H Young, Jonas Eberhard
Feb 3, 2016·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Joseph F HayesDavid P J Osborn
Aug 26, 2016·The Australian and New Zealand Journal of Psychiatry·Sarah SporticheFrank Bellivier
Sep 8, 2017·Journal of Human Genetics·Miao-Miao ZhuZan-Ling Zhang
Nov 4, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic
May 24, 2018·Molecular Diagnosis & Therapy·Claudia PisanuAlessio Squassina
Aug 30, 2019·Bipolar Disorders·Jan ScottUNKNOWN ConLiGen collaborators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

ConLiGen
SPSS

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here